Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements-Reference-Cited by-同舟云学术

Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements

Published:2024-03 Issue:1 Volume:32 Page:101217
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Braun Manuela^ORCID,Lange Claudia,Schatz Philipp,Long Brian,Stanta Johannes,Gorovits Boris,Tarcsa Edit,Jawa Vibha,Yang Tong-Yuan,Lembke Wibke,Miller Nicole,McBlane Fraser,Christodoulou Louis,Yuill Daisy,Milton Mark

Publisher

Elsevier BV

Reference105 articles.

1. Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations;Mendell;Mol. Ther. Methods Clin. Dev.,2022

2. Adeno-associated virus vector as a platform for gene therapy delivery;Wang;Nat. Rev. Drug Discov.,2019

3. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors;Kruzik;Mol. Ther. Methods Clin. Dev.,2019

4. Adeno-associated virus antibody profiles in newborns, children, and adolescents;Calcedo;Clin. Vaccine Immunol.,2011

5. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A;Klamroth;Hum. Gene Ther.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?;Neurotherapeutics;2024-07

2. Biomanufacturing in gene and cell therapy;Molecular Therapy - Methods & Clinical Development;2024-06